Study wrapper · #1391
Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.
Editor's note
FAERS disproportionality analyses can rank reporting patterns, not measure true incidence — reporting is voluntary and confounded by publicity, prescribing volume, and indication. Several of the between-agent differences here are small, with PRRs near 1.0, and rarer outcomes lost significance in sensitivity analyses. The consistent class-wide biliary signal is the durable takeaway, in line with known trial data on gallstone risk; the agent-to-agent rankings should be held loosely.
Plain-language abstract
An analysis of FDA adverse-event reports found gallbladder and bile-duct problems reported across the GLP-1 drug class, with modest differences between agents — tirzepatide showed slightly more gallstone and cholecystitis reports than semaglutide but fewer bile-duct stone reports.